Pulmonary Hypertension Treatment Guidelines

Initial Assessment and Risk Stratification

• Risk stratification is essential to guide therapy intensity, with parameters including clinical evidence of right ventricular failure, functional class, exercise capacity, and hemodynamics, as recommended by the European Respiratory Society 1
• Vasoreactivity testing is recommended for patients with PAH to identify the small subset who may respond to calcium channel blockers, according to the American College of Chest Physicians 2

Treatment Algorithm

• High-dose calcium channel blockers are recommended for the approximately 10% of idiopathic PAH patients who demonstrate acute vasoreactivity, as suggested by the American College of Chest Physicians 2
• Initial oral combination therapy with ambrisentan and tadalafil is recommended as it has proven superior to initial monotherapy in delaying clinical failure, according to the European Society of Cardiology 3
• Initial combination therapy including intravenous prostacyclin analogues is recommended for high-risk PAH patients, as recommended by the European Society of Cardiology 3
• Intravenous epoprostenol should be prioritized as it has reduced the 3-month mortality rate in high-risk PAH patients, according to the European Society of Cardiology 3

Supportive Measures

• Diuretic treatment is indicated in PAH patients with signs of right ventricular failure and fluid retention, as recommended by the European Respiratory Society 4
• Continuous long-term oxygen therapy is indicated when arterial blood O2 pressure is consistently less than 8 kPa (60 mmHg), according to the European Respiratory Society 4
• Oral anticoagulation should be considered in patients with idiopathic PAH, heritable PAH, and PAH due to anorexigens, as suggested by the European Respiratory Society 4
• Supervised exercise rehabilitation should be considered for physically deconditioned patients, according to the European Respiratory Society 4

Advanced Therapies

• Lung transplantation is recommended soon after inadequate clinical response on maximal medical therapy, as suggested by the European Society of Cardiology 3
• Balloon atrial septostomy (BAS) may be considered as a palliative or bridging procedure in patients deteriorating despite maximal medical therapy, according to the European Society of Cardiology 3

Treatment for Other PH Groups

• For Group 2 (PH due to left heart disease), treatment should focus on optimizing the underlying cardiac condition; PAH-specific therapies are not recommended, as suggested by the European Respiratory Society 5
• For Group 4 (Chronic thromboembolic PH), pulmonary endarterectomy is the recommended treatment when feasible, according to the European Respiratory Society 5

Treatment of Pulmonary Hypertension

Initial Treatment and Classification

• The American Thoracic Society recommends initial combination therapy with ambrisentan and tadalafil as the first-line treatment for most patients with pulmonary arterial hypertension (PAH) to improve exercise capacity and delay clinical worsening 6
• Pulmonary hypertension (PH) is classified into five groups based on etiology, with treatment approaches differing significantly between groups 7, 8

Treatment Based on PAH Classification and Risk Stratification

• For non-vasoreactive patients with low or intermediate risk (WHO FC II-III), initial combination therapy with ambrisentan and tadalafil is recommended as it has proven superior to initial monotherapy in delaying clinical failure 6, 9
• For high-risk (WHO FC IV) patients, continuous intravenous epoprostenol should be prioritized as it has reduced the 3-month mortality rate in high-risk PAH patients 9

Supportive Care and General Measures

• The European Society of Cardiology recommends oxygen supplementation to maintain arterial oxygen saturations >90% 7, 8
• Immunization against influenza and pneumococcal pneumonia is recommended 6

Advanced Therapies

• Lung transplantation should be considered for patients with inadequate response to maximal medical therapy 9, 10
• Balloon atrial septostomy may be considered as a palliative or bridging procedure in patients deteriorating despite maximal medical therapy 9, 10

Treatment for Other PH Groups

• For Group 2 (PH due to left heart disease), treatment should focus on optimizing the underlying cardiac condition; PAH-specific therapies are not recommended 7, 11
• For Group 4 (Chronic thromboembolic PH), pulmonary endarterectomy is the treatment of choice when feasible 8, 11

Important Considerations and Pitfalls

• The European Heart Society recommends that patients with PAH should be managed at specialized centers with expertise in pulmonary hypertension 8
• The combination of riociguat and PDE-5 inhibitors (such as sildenafil) is contraindicated due to risk of hypotension 9

Initial Treatment Options for Pulmonary Arterial Hypertension (PAH)

Assessment and Classification

• The American College of Cardiology recommends that all patients with suspected PAH should undergo vasoreactivity testing during right heart catheterization to determine eligibility for calcium channel blocker therapy 12
• Treatment approach should be based on WHO functional class, with different strategies for class II, III, and IV patients 13

Treatment Algorithm Based on Vasoreactivity Status

• The American College of Cardiology recommends high-dose calcium channel blockers (CCBs) for the approximately 10% of idiopathic PAH patients who demonstrate acute vasoreactivity 13
• Long-acting nifedipine, diltiazem, or amlodipine are the preferred CCBs; verapamil should be avoided due to negative inotropic effects 13
• Patients should be closely monitored and if they do not improve to functional class I or II, additional PAH therapy should be instituted 13

Non-vasoreactive Patients

• Initial oral combination therapy with ambrisentan and tadalafil is recommended as it has proven superior to initial monotherapy in delaying clinical failure 13
• For patients unable to tolerate combination therapy, monotherapy options include endothelin receptor antagonists (ERAs): bosentan or ambrisentan 13, 12
• For patients unable or unwilling to manage parenteral prostanoid therapy, inhaled prostanoid in combination with an ERA and PDE-5 inhibitor is advised 13
• Continuous intravenous epoprostenol is strongly recommended as first-line therapy for WHO Functional Class IV patients as it is the only treatment proven to reduce mortality 14

Supportive Measures

• Diuretics are indicated for PAH patients with signs of right ventricular failure and fluid retention 14
• Oxygen supplementation is recommended when arterial blood oxygen pressure is consistently <8 kPa (60 mmHg) 15
• Anticoagulation should be considered in idiopathic PAH, heritable PAH, and anorexigen-induced PAH 14
• Immunization against influenza and pneumococcal infection is recommended 15
• Supervised exercise training should be considered in physically deconditioned PAH patients under medical therapy 15
• Pregnancy is contraindicated in PAH due to 30-50% mortality risk 15

Monitoring and Follow-up

• Regular follow-up every 3-6 months for stable patients, more frequently for advanced disease 14
• Assessment should include functional class, exercise capacity tests (6-minute walk distance), and echocardiographic evaluation 14
• Treatment goals include achieving WHO functional class I or II and a 6-minute walk distance >440m 15

Advanced Options

• For patients with inadequate response to maximal medical therapy, lung transplantation should be considered 14
• Balloon atrial septostomy may be considered as a palliative procedure or bridge to transplantation in selected cases 14